An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Trial Status: Closed to Accrual
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Inclusion Criteria
- Solid cancers that are advanced or have spread (for which alternative therapies were deemed not effective)
- Eastern Cooperative Oncology Group (ECOG) 0-1
- Acceptable lab testing results
- Allow biopsies
Exclusion Criteria
- Central nervous system (CNS) tumors
- Uncontrolled or significant cardiovascular diseases
- Active or known autoimmune disease
- Organ transplant
Illinois
Chicago
Northwestern University
Status: CLOSED_TO_ACCRUAL
Maryland
Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: COMPLETED
Contact: Dung Thi Le
Phone: 410-955-8804
Email:
jhcccro@jhmi.edu
Massachusetts
Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
New York
Buffalo
Roswell Park Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE
New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Richard D. Carvajal
Phone: 212-639-7202
Email:
carvajar@mskcc.org
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: IN_REVIEW
Trial Phase Phase I/II
Trial Type Treatment
Lead Organization
Bristol-Myers Squibb
- Primary ID CA013-004
- Secondary IDs NCI-2016-01162, 2016-000603-91
- Clinicaltrials.gov ID NCT02754141